Get the Stockscreener App
15.66
1.76%
-0.28
Immunovant Inc stock is traded at $15.66, with a volume of 1.09M.
It is down -1.76% in the last 24 hours and up +11.70% over the past month.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.
See More
Previous Close:
$15.94
Open:
$15.67
24h Volume:
1.09M
Relative Volume:
0.62
Market Cap:
$2.87B
Revenue:
-
Net Income/Loss:
$-382.71M
P/E Ratio:
-5.9771
EPS:
-2.62
Net Cash Flow:
$-325.64M
1W Performance:
-6.62%
1M Performance:
+11.70%
6M Performance:
-40.41%
1Y Performance:
-41.13%
1-Day Range:
$15.35
$16.08
1-Week Range:
$15.35
$17.14
52-Week Range:
$12.72
$34.47
Immunovant Inc Stock (IMVT) Company Profile
Name
Immunovant Inc
Sector
Industry
Phone
917-580-3099
Address
320 WEST 37TH STREET, NEW YORK, NY
Compare IMVT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMVT
Immunovant Inc
|
15.66 | 2.87B | 0 | -382.71M | -325.64M | -2.62 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-03-25 | Initiated | Jefferies | Hold |
| Jan-03-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Oct-09-24 | Reiterated | Oppenheimer | Outperform |
| Mar-28-24 | Initiated | Oppenheimer | Outperform |
| Mar-13-24 | Initiated | Goldman | Buy |
| Feb-20-24 | Initiated | JP Morgan | Overweight |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-13-23 | Upgrade | UBS | Neutral → Buy |
| Sep-26-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-01-23 | Initiated | BofA Securities | Buy |
| Apr-25-23 | Initiated | Citigroup | Buy |
| Mar-31-23 | Initiated | Piper Sandler | Overweight |
| Mar-30-23 | Initiated | Stifel | Buy |
| Feb-15-23 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-13-23 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-03-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Sep-26-22 | Downgrade | UBS | Buy → Neutral |
| Dec-08-21 | Initiated | Wells Fargo | Equal Weight |
| Aug-03-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Aug-02-21 | Downgrade | Credit Suisse | Neutral → Underperform |
| Jun-01-21 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-01-21 | Downgrade | Stifel | Buy → Hold |
| Oct-28-20 | Initiated | UBS | Buy |
| Oct-12-20 | Initiated | Guggenheim | Buy |
| Oct-08-20 | Initiated | Stifel | Buy |
| Oct-02-20 | Initiated | Credit Suisse | Outperform |
| Aug-26-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Jul-29-20 | Initiated | H.C. Wainwright | Buy |
| Feb-24-20 | Initiated | SVB Leerink | Outperform |
View All
Immunovant Inc Stock (IMVT) Latest News
Learn to Evaluate (IMVT) using the Charts - news.stocktradersdaily.com
Immunovant, Inc. (NASDAQ:IMVT) Receives $38.33 Consensus Target Price from Brokerages - Defense World
Immunovant: Navigating The Complexities Of The FcRn Landscape (Downgrade) - Seeking Alpha
Cantor Fitzgerald Forecasts Immunovant FY2027 Earnings - Defense World
Immunovant, Inc. (NASDAQ:IMVT) Shares Sold by Wellington Management Group LLP - Defense World
Two Sigma Advisers LP Buys New Position in Immunovant, Inc. (NASDAQ:IMVT) - Defense World
Ameriprise Financial Inc. Makes New Investment in Immunovant, Inc. (NASDAQ:IMVT) - Defense World
Immunovant (IMVT) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Long Term Trading Analysis for (IMVT) - news.stocktradersdaily.com
Leerink Partnrs Estimates Immunovant FY2030 Earnings - Defense World
IMVT Q4 Loss Narrower Than Expected, Stock Up, Pipeline in Focus - MSN
Immunovant price target lowered to $35 from $51 at H.C. Wainwright - TipRanks
Immunovant’s Promising Future: Buy Rating Backed by Strategic Advancements and Strong Cash Position - TipRanks
Immunovant Inc reports results for the quarter ended March 31Earnings Summary - TradingView
H.C. Wainwright Adjusts Price Target for Immunovant (IMVT) Amid Future Prospects | IMVT Stock News - GuruFocus
Immunovant Insiders Sell US$5.9m Of Stock, Possibly Signalling Caution - simplywall.st
Immunovant (NASDAQ:IMVT) Shares Gap Up After Better-Than-Expected Earnings - Defense World
Immunovant, Inc. Reports Strategic Progress and Financial Results - TipRanks
IMVT INVESTIGATION ALERT: Investigation Launched into Private Placement Transaction by Immunovant, Inc. and Attorneys Encourage Investors to Contact Law Firm - The Malaysian Reserve
Immunovant, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2025 - marketscreener.com
Immunovant Stock Rises On Narrower-Than-Expected Q1 Loss: Retail’s Still On The Fence By Stocktwits - Investing.com India
Immunovant Stock Rises On Narrower-Than-Expected Q1 Loss: Retail’s Still On The Fence - MSN
Immunovant, Inc. SEC 10-K Report - TradingView
Immunovant (IMVT) Secures Strong Financial Position with $714 Million in Cash | IMVT Stock News - GuruFocus
Immunovant's Fiscal Q4 Net Loss Widens - marketscreener.com
Earnings Flash (IMVT) IMMUNOVANT INC. Reports Q4 Loss $0.64 Per Share, vs. FactSet Est of $-0.71 - marketscreener.com
Immunovant's Clinical Trials Show 74% Success in Myasthenia Gravis, Advancing 6 Disease Programs - Stock Titan
Immunovant (IMVT) to Release Earnings on Wednesday - Defense World
Bank of America Corp DE Buys 114,511 Shares of Immunovant, Inc. (NASDAQ:IMVT) - Defense World
(IMVT) Trading Advice - news.stocktradersdaily.com
IMVT INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into a Private Placement Transaction by Immunovant, Inc. and Encourages Investors to Contact the Firm - Business Wire
Brokerages Set Immunovant, Inc. (NASDAQ:IMVT) Target Price at $38.33 - Defense World
Immunovant, Inc. (NASDAQ:IMVT) Shares Bought by Northern Trust Corp - Defense World
Is Immunovant, Inc. (IMVT) The Most Undervalued Stock With Smart Money Ratings? - Insider Monkey
The Manufacturers Life Insurance Company Has $889,000 Stock Position in Immunovant, Inc. (NASDAQ:IMVT) - Defense World
Transcript : Immunovant, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 04 - marketscreener.com
Smart Money Ratings For 20 Most Undervalued Stocks - Insider Monkey
Immunovant Inc (NASDAQ: IMVT) Is The Among Hot Stock Right Now - Stocksregister
Dimensional Fund Advisors LP Sells 58,463 Shares of Immunovant, Inc. (NASDAQ:IMVT) - Defense World
Is Immunovant, Inc. (IMVT) The Best Stock That Will Bounce Back? - Insider Monkey
Raymond James Financial Inc. Buys Shares of 20,382 Immunovant, Inc. (NASDAQ:IMVT) - Defense World
11 Stocks That Will Bounce Back According to Analysts - Insider Monkey
Investor’s Delight: Immunovant Inc (IMVT) Closes Weak at 15.22, Down -3.67 - DWinneX
Ins & Outs: Biopharma players shuffle c-suite ranks - BioProcess International
(IMVT) Investment Analysis - news.stocktradersdaily.com
Immunovant, Inc. (NASDAQ:IMVT) Shares Acquired by Wells Fargo & Company MN - Defense World
A company insider recently sold 1,925 shares of Immunovant Inc [IMVT]. Should You Sale? - knoxdaily.com
IMVT’s Stock Market Adventure: -34.80% YTD Growth Amidst Volatility - investchronicle.com
Thyroid Eye Disease Pipeline 2025: MOA, ROA, and Clinical Trial - openPR.com
Thyroid Eye Disease Pipeline 2025: MOA, ROA, and Clinical Trial Insights Explored by DelveInsight | Immunovant Sciences, Novartis, Viridian Therapeutics, Sling Therapeutics, Regeneron Pharma - Barchart.com
Perhaps timely catching Immunovant Inc (IMVT) would be a good idea - Sete News
Immunovant Inc Stock (IMVT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.91%
1.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):